- Home
- TSVT vs AOMR Comparison
TSVT vs AOMR Comparison
Compare TSVT & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- AOMR
- Stock Information
- Founded
- TSVT 2021
- AOMR 2018
- Country
- TSVT United States
- AOMR United States
- Employees
- TSVT N/A
- AOMR N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- AOMR Real Estate Investment Trusts
- Sector
- TSVT Health Care
- AOMR Real Estate
- Exchange
- TSVT Nasdaq
- AOMR Nasdaq
- Market Cap
- TSVT 160.4M
- AOMR 219.8M
- IPO Year
- TSVT N/A
- AOMR 2021
- Fundamental
- Price
- TSVT $3.07
- AOMR $9.33
- Analyst Decision
- TSVT Buy
- AOMR Buy
- Analyst Count
- TSVT 6
- AOMR 6
- Target Price
- TSVT $10.40
- AOMR $12.10
- AVG Volume (30 Days)
- TSVT 270.9K
- AOMR 91.3K
- Earning Date
- TSVT 11-12-2024
- AOMR 11-06-2024
- Dividend Yield
- TSVT N/A
- AOMR 13.93%
- EPS Growth
- TSVT N/A
- AOMR N/A
- EPS
- TSVT N/A
- AOMR 2.91
- Revenue
- TSVT $45,620,000.00
- AOMR $94,441,000.00
- Revenue This Year
- TSVT N/A
- AOMR N/A
- Revenue Next Year
- TSVT $36.09
- AOMR $31.91
- P/E Ratio
- TSVT N/A
- AOMR $3.16
- Revenue Growth
- TSVT N/A
- AOMR 455.18
- 52 Week Low
- TSVT $2.78
- AOMR $8.88
- 52 Week High
- TSVT $6.40
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- TSVT 32.27
- AOMR 44.36
- Support Level
- TSVT $2.78
- AOMR $8.95
- Resistance Level
- TSVT $4.07
- AOMR $9.34
- Average True Range (ATR)
- TSVT 0.24
- AOMR 0.21
- MACD
- TSVT -0.05
- AOMR -0.02
- Stochastic Oscillator
- TSVT 12.02
- AOMR 37.57
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.